BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) CEO Jean Jacques Bienaime sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $94.85, for a total value of $2,845,500.00. Following the transaction, the chief executive officer now directly owns 426,213 shares in the company, valued at $40,426,303.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Monday, April 10th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $99.56, for a total transaction of $995,600.00.
- On Thursday, April 6th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $96.13, for a total transaction of $961,300.00.
- On Friday, March 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $92.28, for a total value of $1,384,200.00.
- On Monday, March 13th, Jean Jacques Bienaime sold 8,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $90.45, for a total value of $723,600.00.
- On Monday, February 13th, Jean Jacques Bienaime sold 6,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $109.15, for a total value of $654,900.00.
- On Friday, February 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $110.11, for a total value of $1,651,650.00.
BioMarin Pharmaceutical Trading Down 1.5 %
BMRN opened at $93.93 on Friday. The business has a 50 day simple moving average of $94.81 and a two hundred day simple moving average of $99.62. BioMarin Pharmaceutical Inc. has a one-year low of $70.73 and a one-year high of $117.77. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.75 and a quick ratio of 3.21. The firm has a market capitalization of $17.63 billion, a price-to-earnings ratio of 247.18 and a beta of 0.38.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last issued its quarterly earnings results on Monday, February 27th. The biotechnology company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). BioMarin Pharmaceutical has a return on equity of 4.02% and a net margin of 3.30%. The company had revenue of $537.54 million during the quarter, compared to the consensus estimate of $533.88 million. Analysts predict that BioMarin Pharmaceutical Inc. will post 1.06 EPS for the current year.
Hedge Funds Weigh In On BioMarin Pharmaceutical
A number of institutional investors and hedge funds have recently modified their holdings of the company. TCI Wealth Advisors Inc. raised its position in BioMarin Pharmaceutical by 68.0% in the fourth quarter. TCI Wealth Advisors Inc. now owns 247 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 100 shares during the period. Commonwealth Equity Services LLC grew its holdings in BioMarin Pharmaceutical by 2.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,454 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 110 shares during the period. Xponance Inc. raised its stake in shares of BioMarin Pharmaceutical by 3.2% in the third quarter. Xponance Inc. now owns 3,584 shares of the biotechnology company’s stock worth $304,000 after buying an additional 112 shares during the period. Caprock Group LLC increased its stake in shares of BioMarin Pharmaceutical by 6.1% in the first quarter. Caprock Group LLC now owns 2,065 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 118 shares in the last quarter. Finally, Amalgamated Bank raised its position in shares of BioMarin Pharmaceutical by 0.7% during the 4th quarter. Amalgamated Bank now owns 18,439 shares of the biotechnology company’s stock valued at $1,908,000 after purchasing an additional 123 shares during the period. 96.26% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages have recently issued reports on BMRN. Sanford C. Bernstein began coverage on shares of BioMarin Pharmaceutical in a research note on Tuesday, March 21st. They set an “underperform” rating and a $81.00 price target for the company. Stifel Nicolaus lifted their price objective on BioMarin Pharmaceutical from $114.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, February 28th. 888 reaffirmed a “maintains” rating on shares of BioMarin Pharmaceutical in a report on Thursday, April 27th. Oppenheimer lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 22nd. Finally, StockNews.com upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Friday, April 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $118.65.
About BioMarin Pharmaceutical
(Get Rating)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.
Featured Stories
Receive News & Ratings for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.